Stuart A. Arbuckle - 18 Jun 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Director
Signature
/s/ Hunter Smith, attorney-in-fact for Stuart A. Arbuckle
Issuer symbol
RYTM
Transactions as of
18 Jun 2024
Net transactions value
$0
Form type
4
Filing time
20 Jun 2024, 21:38:51 UTC
Previous filing
17 May 2024
Next filing
25 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (right to buy) Award $0 +14,000 $0.000000 14,000 18 Jun 2024 Common Stock 14,000 $41.39 Direct F1
transaction RYTM Restricted Stock Units Award $0 +4,000 $0.000000 4,000 18 Jun 2024 Common Stock 4,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.